Innocan Pharma’s Liposomal CBD Achieves Breakthrough in Vet and Human Pain Relief

An update from InnoCan Pharma ( (TSE:INNO) ) is now available.

Innocan Pharma reported a significant breakthrough with its liposomal CBD injection, LPT-CBD, in providing rapid and sustained pain relief for an elderly donkey suffering from osteoarthritis. This successful treatment highlights the potential of LPT-CBD as a non-opioid alternative for chronic pain management in both veterinary and human applications. The company’s recent pre-IND meeting with the FDA further supports its potential use for human pain management, positioning Innocan as a prominent player in innovative pain relief solutions.

More about InnoCan Pharma

Innocan Pharma is an innovator in the pharmaceutical and wellness sectors, known for developing a CBD-loaded liposome drug delivery platform aimed at non-opioid pain management. In addition to pharmaceuticals, Innocan markets a variety of self-care and beauty products through its subsidiary BI Sky Global Ltd., focusing on online sales.

YTD Price Performance: -7.35%

Average Trading Volume: 14,000

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $36.99M

For a thorough assessment of INNO stock, go to TipRanks’ Stock Analysis page.